Log In
Print
BCIQ
Print
Print this Print this
 

afacifenacin fumarate (SMP-986)

  Manage Alerts
Collapse Summary General Information
Company Dainippon Sumitomo Pharma Co. Ltd.
DescriptionDual muscarinic receptor antagonist and sodium channel blockade inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationIncontinence
Indication DetailsTreat overactive bladder (OAB)
Regulatory Designation

Partner

Nippon Shinyaku Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today